羚锐制药(600285) - 2024 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders of the listed company was ¥190,378,639.92, representing a year-on-year increase of 31.98%[18] - Basic earnings per share increased to ¥0.340, up 30.77% year-on-year[18] - The weighted average return on net assets rose to 6.59%, an increase of 1.09 percentage points[18] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 31.55%, primarily due to an increase in sales revenue[22] - The total profit for the period was approximately 220.82 million yuan, compared to 169.95 million yuan in the previous year[32] - The company reported a net profit of CNY 220,826,418.61 for Q1 2024, up from CNY 170,629,996.52 in Q1 2023, representing a growth of 29.4%[46] Revenue and Costs - Operating revenue for the first quarter was ¥909,046,867.70, reflecting a growth of 15.27% compared to the same period last year[18] - Total operating revenue for Q1 2024 reached CNY 909,046,867.70, an increase of 15.2% compared to CNY 788,648,249.06 in Q1 2023[46] - Total operating costs for Q1 2024 were CNY 696,497,752.04, up from CNY 622,764,688.53 in Q1 2023, reflecting a growth of 11.8%[46] Assets and Equity - Total assets at the end of the reporting period reached ¥4,981,554,316.97, an increase of 4.39% compared to the end of the previous year[5] - Shareholders' equity attributable to shareholders of the listed company was ¥2,934,067,847.86, up 5.12% from the previous year[5] - The company's total equity reached CNY 2,941,689,710.88 as of March 31, 2024, compared to CNY 2,798,696,938.00 at the end of 2023, indicating a growth of 5.1%[43] Cash Flow - Net cash flow from operating activities was ¥44,906,293.79, a decrease of 44.91% compared to the previous year[18] - The net cash flow from operating activities decreased by 44.91%, mainly due to a reduction in cash collections and an increase in payable amounts[22] - Net cash flow from operating activities for Q1 2024 was CNY 44,906,293.79, a decrease of 45% from CNY 81,521,628.54 in Q1 2023[49] - The net increase in cash and cash equivalents was -23,997,997.85, compared to an increase of 241,987,944.29 in the previous period[51] - Cash and cash equivalents at the end of the period totaled 1,466,278,009.71, down from 1,421,283,621.04 in the previous period[51] Investments and Financing - The company received government subsidies amounting to ¥2,272,384.03, which are closely related to its normal business operations[5] - Net cash flow from investing activities was -57,440,536.53, compared to 142,373,586.31 in the previous period[51] - Total cash inflow from financing activities was 8,612,408.51, while cash outflow was 20,076,857.67, resulting in a net cash flow of -11,464,449.16[51] - Cash received from borrowings was 38,792,765.60, while cash paid for debt repayment was 20,000,000.00[51] Research and Development - Research and development expenses for Q1 2024 were CNY 20,393,113.38, a decrease of 3.8% from CNY 21,205,202.59 in Q1 2023[46] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22]